Review
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Psychiatry. Jan 19, 2022; 12(1): 77-97
Published online Jan 19, 2022. doi: 10.5498/wjp.v12.i1.77
Brain-derived neurotrophic factor and inflammation in depression: Pathogenic partners in crime?
Grace A Porter, Jason C O’Connor
Grace A Porter, Department of Pharmacology, UT Health San Antonio, San Antonio, TX 78229, United States
Jason C O’Connor, Department of Pharmacology, University of Texas Health San Antonio, San Antonio, TX 78229, United States
Jason C O’Connor, Audie L. Murphy VA Hospital, South Texas Veterans Health System, San Antonio, TX 78229, United States
Author contributions: Porter G contributed to content decisions, prepared initial draft and figures, and edited the revised submission; O'Connor J contributed to content decisions, supervised initial draft and figures, prepared response to reviewers and final drafts for both initial and revised submission.
Supported by National Institutes of Health, No. TL1 TR002647; Veterans Affairs, No. I01BX003195.
Conflict-of-interest statement: The authors declare no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jason C O’Connor, PhD, Associate Professor, Department of Pharmacology, University of Texas Health San Antonio, 216B Medical Building MC-7764, 7703 Floyd Curl Drive, San Antonio, TX 78229, United States. oconnorj@uthscsa.edu
Received: April 28, 2021
Peer-review started: April 28, 2021
First decision: July 14, 2021
Revised: July 21, 2021
Accepted: December 2, 2021
Article in press: December 2, 2021
Published online: January 19, 2022
Processing time: 264 Days and 11 Hours
Abstract

Major depressive disorder is a debilitating disorder affecting millions of people each year. Brain-derived neurotrophic factor (BDNF) and inflammation are two prominent biologic risk factors in the pathogenesis of depression that have received considerable attention. Many clinical and animal studies have highlighted associations between low levels of BDNF or high levels of inflammatory markers and the development of behavioral symptoms of depression. However, less is known about potential interaction between BDNF and inflammation, particularly within the central nervous system. Emerging evidence suggests that there is bidirectional regulation between these factors with important implications for the development of depressive symptoms and anti-depressant response. Elevated levels of inflammatory mediators have been shown to reduce expression of BDNF, and BDNF may play an important negative regulatory role on inflammation within the brain. Understanding this interaction more fully within the context of neuropsychiatric disease is important for both developing a fuller understanding of biological pathogenesis of depression and for identifying novel therapeutic opportunities. Here we review these two prominent risk factors for depression with a particular focus on pathogenic implications of their interaction.

Keywords: Brain-derived neurotrophic factor; Microglia; Neuroinflammation; Growth factors; Depression

Core Tip: Low levels of brain-derived neurotrophic factor (BDNF) and high inflammation have both been implicated as risk factors in the pathogenesis of major depressive disorder. Here we review the role BDNF and inflammation play in the etiology of depression and the interaction between them. Recent evidence suggests a bidirectional connection between these two risk factors: inflammation reduces BDNF expression, and BDNF may have a negative regulatory role in resolving neuroinflammation. Understanding of this interaction in the context of neuropsychiatric disease is important for a fuller understanding of biological pathogenesis of depression and for identifying novel therapeutic opportunities.